You just read:

ERLEADA® (apalutamide) Significantly Improved Overall Survival (OS) and Radiographic Progression-Free Survival (rPFS) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

May 31, 2019, 17:57 ET